Artificial intelligence in nanomedicine.,Nanoscale Horizons

当前位置： X-MOL 学术 › Nanoscale Horiz. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Artificial intelligence in nanomedicine.
Nanoscale Horizons ( IF 8.0 ) Pub Date : 2018-10-15 , DOI: 10.1039/c8nh00233a
Dean Ho ₁ , Peter Wang , Theodore Kee

Affiliation

The field of nanomedicine has made substantial strides in the areas of therapeutic and diagnostic development. For example, nanoparticle-modified drug compounds and imaging agents have resulted in markedly enhanced treatment outcomes and contrast efficiency. In recent years, investigational nanomedicine platforms have also been taken into the clinic, with regulatory approval for Abraxane® and other products being awarded. As the nanomedicine field has continued to evolve, multifunctional approaches have been explored to simultaneously integrate therapeutic and diagnostic agents onto a single particle, or deliver multiple nanomedicine-functionalized therapies in unison. Similar to the objectives of conventional combination therapy, these strategies may further improve treatment outcomes through targeted, multi-agent delivery that preserves drug synergy. Also, similar to conventional/unmodified combination therapy, nanomedicine-based drug delivery is often explored at fixed doses. A persistent challenge in all forms of drug administration is that drug synergy is time-dependent, dose-dependent and patient-specific at any given point of treatment. To overcome this challenge, the evolution towards nanomedicine-mediated co-delivery of multiple therapies has made the potential of interfacing artificial intelligence (AI) with nanomedicine to sustain optimization in combinatorial nanotherapy a reality. Specifically, optimizing drug and dose parameters in combinatorial nanomedicine administration is a specific area where AI can actionably realize the full potential of nanomedicine. To this end, this review will examine the role that AI can have in substantially improving nanomedicine-based treatment outcomes, particularly in the context of combination nanotherapy for both N-of-1 and population-optimized treatment.

中文翻译：

纳米医学中的人工智能。

纳米医学领域在治疗和诊断开发领域取得了长足的进步。例如，纳米粒子修饰的药物化合物和显像剂已显着提高了治疗效果和造影剂效率。近年来，用于研究的纳米药物平台也已进入临床，并获得了Abraxane®和其他产品的监管批准。随着纳米医学领域的不断发展，已探索出多功能方法来将治疗剂和诊断剂同时整合到单个颗粒上，或同时提供多种纳米医学功能化的疗法。与常规联合疗法的目标相似，这些策略可以通过针对性，多药物递送，可保持药物协同作用。而且，类似于常规/未修饰的联合疗法，经常以固定剂量研究基于纳米药物的药物递送。在所有形式的药物给药中，持续存在的挑战是，在任何给定的治疗点上，药物协同作用都是时间依赖性，剂量依赖性和患者特异性的。为了克服这一挑战，向纳米药物介导的多种疗法共输送的发展已使将人工智能（AI）与纳米药物相结合的潜力来维持组合纳米疗法的优化成为现实。具体来说，在组合纳米药物管理中优化药物和剂量参数是AI可以切实发挥纳米药物全部潜力的一个特定领域。为此，

更新日期：2018-10-04

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11